AI Stock Memo: VRTX - Vertex - RankAlpha

VRTX

Rating buyAI Memo

Vertex

As of 2026-02-14/Confidence medium

Open ticker Back to Memos

Data freshness

AI Memo

As of 2026-02-14 • Model: RankAlpha Sentiment AI

Decision Panel

Action, confidence, horizon, and decision blockers at a glance.

Action

buy

Confidence

medium

Horizon

—

Key catalyst

Pipeline readouts / regulatory filings • 2026-09-30

Expected move: +11%

Biggest risk

Regulatory setbacks, negative pivotal data, or CF sales weakness compress multiples and push fair value toward the low end of consensus ranges.

Invalidation

Break below $330 or thesis failure.

What would change my mind?

CFTR franchise remains strong while new modalities (gene/gene-editing) deliver positive readouts or approvals, lifting revenue visibility and multiple expansion toward the high end of consensus.

Research note

Recommendation

buy

Confidence

medium

As of

2026-02-14

Base target

$530

p=60%

Bull target

$656

p=20%

Bear target

$330

p=20%

Key bullets

Fast scan of bull, bear, and watch items

BullKey bullets

Q1 FY2026 results (estimated)
Commercial growth and label expansion
CFTR franchise remains strong while new modalities (gene/gene-editing) deliver positive readouts or approvals, lifting revenue visibility and multiple expansion toward the high end of consensus.

BearKey bullets

CFTR sales deceleration or payer pressure
Negative pivotal readouts or safety issues
Regulatory delays or adverse label decisions

WatchKey bullets

Pipeline readouts / regulatory filings

Summary

High-level snapshot

Recommendation

buy

Model confidence

medium

Timeframe

Asset

Equity

Trigger

Base case: $530 (p=60%)

Bull/Bear spread: +38% / -31%

Vs latest close: Bull +38% · Base +11% · Bear -31%

Scenario probabilities

Bull Target: $656 (p=20%)Base Target: $530 (p=60%)Bear Target: $330 (p=20%)

Commentary

Consensus shows modest upside from the anchor with wide dispersion (low ~330, high ~656). Market tone is cautiously constructive; near-term sentiment will hinge on earnings and R&D outcomes, and the buy view rests on asymmetric upside from successful catalysts despite a modest base uplift.

As of 2026-02-14 • Updated bi-weekly / post-earningsSource: Internal modelMethodology

Analyst Summary

Thesis highlights from the latest analysis

Bull Case

CFTR franchise remains strong while new modalities (gene/gene-editing) deliver positive readouts or approvals, lifting revenue visibility and multiple expansion toward the high end of consensus.

Bear Case

Regulatory setbacks, negative pivotal data, or CF sales weakness compress multiples and push fair value toward the low end of consensus ranges.

Drivers

Scannable catalysts and supporting factors

Q1 FY2026 results (estimated)
Commercial growth and label expansion

Human Analyst Targets

External snippets for comparison only; verify at source.

Unverified externalLast fetched 2026-02-14Source quality: external scrape

External snippets are unverified; treat as directional signals only. Always confirm with the original provider.

Inline RA est

Provider

serper

Median (USD)

$530.16

Range (USD)

$330.00 - $656.25

Count

Query: Vertex Pharmaceuticals Inc Common (VRTX) analyst consensus price target high low average

Vertex Pharmaceuticals (VRTX) Stock Forecast and Price Target 2026
Search result #1
According to the 27 analysts' twelve-month price targets for Vertex Pharmaceuticals, the average price target is $537.05. The highest price target for VRTX is ...
Extracted: $537.05Open source
Vertex Pharmaceuticals (VRTX) Price Targets - Zacks
Search result #2
The forecasts range from a low of $330.00 to a high of $625.00. The average price target represents an increase of 11.04% from the last closing price of $465. ...
Extracted: $330.00, $625.00, $465.00Open source
Vertex (VRTX) Stock Forecast & Price Target - Investing.com
Search result #3
According to projections from 25 analysts, the average 12-month price target for Vertex is 514.32, with a high estimate of 625 and a low estimate of 330. What ...
Open source
Vertex Pharmaceuticals Inc. Analyst Estimates - VRTX - MarketWatch
Search result #4
Stock Price Targets. High, $625.00. Median, $540.50. Low, $330.00. Average, $530.31. Current Price, $465.02. Yearly Numbers. Estimates. VRTX will report 2026 ...
Extracted: $625.00, $540.50, $330.00, $530.31, $465.02Open source
Vertex Pharmaceuticals Incorporated (VRTX) Stock Price, News ...
Search result #5
Q4. FY25. 0. 1B. 2B. 3B. View More. Analyst Insights: VRTX. View More. Analyst Price Targets. 330.00 Low. 517.12 Average. 491.47 Current. 625.00 High. Analyst ...
Open source
Vertex Pharmaceuticals: VRTX Stock Price Quote & News | Robinhood
Search result #6
Morgan Stanley analyst Terence Flynn raised the firm's price target on Vertex Pharmaceuticals (VRTX) to $570 from $564 and keeps an Overweight rating on the sha ...
Extracted: $570.00, $564.00Open source

Scenarios

Bull Target (Scenario probability)

$656 / p=20% prob

Base Target (Scenario probability)

$530 / p=60% prob

Bear Target (Scenario probability)

$330 / p=20% prob

Price $476 as of 2026-07-14

Nearest Scenario: Base (∆ 11%)

Targets vs latest close: Bull +38% · Base +11% · Bear -31%

Sentiment & Exposure

Sentiment unavailable: insufficient coverage

Events

Other notable items detected

EVENT2026-09-30
Pipeline readouts / regulatory filings
Phase readouts or regulatory submissions for non-CF programs could materially shift growth expectations; date is a conservative window end.
Prob 40.00% • Move 12.00% • Priced-in 20.00%

Short-term Catalysts

Next few weeks

Q1 FY2026 results (estimated)
2026-05-15
Quarterly results and guidance could prompt near-term re-pricing; date estimated on typical reporting cadence.
Prob 60% • Move 8% • Priced-in 30%

Long-term Catalysts

Months to a year

Commercial growth and label expansion
2027-02-14
Sustained CFTR uptake, label expansions, or commercialization of new indications would underpin medium-term re-rating; date set conservatively at one year.
Prob 55% • Move 25% • Priced-in 40%

Risks

CFTR sales deceleration or payer pressure
Negative pivotal readouts or safety issues
Regulatory delays or adverse label decisions

Peers

Symbol	Summary
REGN	Large-cap biotech with commercial and R&D balance; useful comparator for launch execution and scale risks.
AMGN	Mature commercial biopharma; reference for execution and margin stability at scale.
GILD	Large specialty pharma with durable franchises; a benchmark for sustainable revenue/margin profiles.

Sources

Internal and external references used in this analysis

Model source: RankAlpha Sentiment AI
Human targets: serper
Targets query: Vertex Pharmaceuticals Inc Common (VRTX) analyst consensus price target high low average
Analysis date: 2026-02-14